and V.M.; writingoriginal draft preparation, C.T. 2024 were selected from PubMed/MEDLINE, Embase, Scopus, and Web of Science. The search was conducted using the following keywords: cytomegalovirus, child, and immunocompetent. The target populace ranged from 0 to 17 years of age, with congenital and perinatal infections excluded. Despite the clinical significance of CMV in immunocompetent infants and children, there is a lack of consensus on the use and duration of antiviral therapy. This article aims to enhance clinicians understanding of the various presentations of CMV contamination in immunocompetent children, with the goal of facilitating earlier diagnosis and appropriate management. The reviewed papers indicated that postnatal CMV results in liver symptoms in 67% of cases, followed by hematological disorders and gastrointestinal pathology. In older children, primary contamination leads to liver disease in 51% of cases, with greater neurological and pulmonary involvement compared to that in infants. By highlighting the wide-ranging clinical effects of CMV, we hope to improve physicians ability to recognize and subsequently treat this often overlooked condition in pediatric patients. Keywords:cytomegalovirus, immunocompetent, postnatal, primary, infant, children == 1. Introduction == Cytomegalovirus (CMV), a member of theHerpesviridaefamily, is usually a ubiquitous computer virus that commonly infects individuals of all ages, making it one of the most prevalent viral infections worldwide. The global seroprevalence of CMV depends on sex, age, race, ethnicity, socioeconomic status, and education level. Among adult men Propiolamide it varies from 39.3% to 48% [1], and among women of reproductive age, it is estimated at 86% [1], although it varies regionally. In Canada and the United States among women with childbearing potential, it ranges from 25% to 81%, while in Europe, it ranges from 46% to 96%. Additionally, seroprevalence increases with age. In the United States and Canada, 47% of individuals aged 1220 years Propiolamide are seropositive, while 6770% of those aged 4050 years show evidence of prior contamination [2]. CMV can be transmitted through direct contact with nearly all body fluids, including saliva, tears, urine, stool, breast milk, and semen from infected individuals [3]. The computer virus has been shown to remain viable for up to 6 h on surfaces, making transmission via fomites possible. Additionally, CMV can be efficiently transmitted through transplanted organs and blood transfusions [4,5,6,7]. The natural history of CMV contamination is complex, involving three distinct types of contamination [8]: primary contamination, secondary infection or reactivation, and reinfection. Primary contamination occurs when an individual who has not been previously immunized is usually infected for the first time. After primary contamination, the computer virus establishes a latency period in the body. In some cases, the computer virus can reactivate, resulting in a secondary contamination. Additionally, reinfection or superinfection may occur if a person previously infected with CMV is usually exposed to a different strain of the computer virus, even if sufficient immunity has developed. The clinical presentation of CMV contamination varies considerably depending on the timing of infectionwhether congenital, perinatal, or Rabbit polyclonal to PPAN postnatalas well as the childs immune status (primary contamination in immunocompromised vs. immunocompetent individuals). Each stage and type of contamination can lead to a distinct clinical course. Congenital Propiolamide CMV contamination (cCMV) occurs when the computer virus is transmitted in utero. Transmission can occur in two ways: through a primary contamination in a seronegative woman who acquires CMV during pregnancy or through the reactivation of Propiolamide a latent contamination or reinfection with a new CMV strain in a seropositive pregnant woman. Congenital CMV contamination is typically defined by a positive CMV test within three weeks after birth. It is a common contamination among newborns, with a Propiolamide higher prevalence in low- and middle-income countries compared to that in high-income countries [9]. Around 1015% of infants with cCMV show symptoms at birth, while the remaining 8590% are asymptomatic at birth [10]..